Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trial
- 10 March 1997
- journal article
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 123 (3) , 173-179
- https://doi.org/10.1007/s004320050046
Abstract
No abstract availableThis publication has 0 references indexed in Scilit: